Cost-effectiveness of particle therapy: Current evidence and future needs

被引:42
|
作者
Pijls-Johannesma, Madelon [1 ]
Pommier, Pascal [2 ]
Lievens, Yolande [3 ]
机构
[1] Univ Med Ctr, Maastricht Radiat Oncol MAASTRO Clin, NL-6229 ET Maastricht, Netherlands
[2] Canc Ctr Leon Berard, Dept Radiat Oncol, Lyon, France
[3] Univ Hosp Gasthuisberg, Dept Radiat Oncol, B-3000 Louvain, Belgium
关键词
Particles; Hadron; Ion; Proton; Radiotherapy; Cost-effectiveness; Reimbursement;
D O I
10.1016/j.radonc.2008.07.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Questions are being raised regarding the cost of particle therapy (PT), and with them criticism that PT is too expensive to allow the expected gain in effectiveness. This paper aims to get more insight in the cost and cost-effectiveness of particle therapy and to discuss a future strategy that allows for critical assessment of this health technology. Material and methods: A systematic literature review based on an earlier published comprehensive review was performed and updated until June 1st 2008. Besides, current business plans of PT projects were examined. Additionally, results retrieved from a cost-simulation tool developed under auspice of the ENLIGHT were discussed. Results: The current literature on cost-effectiveness of PT is scarce, non-comparable, and largely not performed according to standard health technology assessment criteria. Besides, different perspectives for cost evaluations have been used, making it difficult to compare and to determine the relative impact in terms of costs for this new treatment modality. Conclusions: Evidence on the cost-effectiveness of PT is scarce. Adequate reimbursement is necessary to support such innovative yet costly treatments. For now, model-based economic evaluations performed at least from a health care perspective may help us to gain evidence-based insight into cost-effectiveness. (c) 2008 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 89 (2008) 127-134.
引用
收藏
页码:127 / 134
页数:8
相关论文
共 50 条
  • [41] Cost-effectiveness of cardiac resynchronization therapy
    Martignani, Cristian
    Massaro, Giulia
    Diemberger, Igor
    Ziacchi, Matteo
    Angeletti, Andrea
    Galie, Nazzareno
    Biffi, Mauro
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (12) : 1375 - 1378
  • [42] Cost-effectiveness of therapy in nonatrial fibrillation
    Wiesel, J
    ANNALS OF INTERNAL MEDICINE, 1999, 131 (12) : 979 - 979
  • [43] Evaluating the cost-effectiveness of therapy for acne
    Weiss, S
    Kimball, A
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P18 - P18
  • [44] COST-EFFECTIVENESS ANALYSIS OF THE THERAPY OF ENDOMETRIOSIS
    Tuletova, A.
    Dochshanova, A.
    Skakova, R.
    VALUE IN HEALTH, 2014, 17 (07) : A511 - A511
  • [45] Cost-effectiveness of intrathecal baclofen therapy versus current therapies in disabled spasticity
    Beresniak, A.
    Bensmail, D.
    Ward, A.
    Wissel, J.
    Motta, F.
    Saltuari, L.
    Lissens, J.
    Cros, S.
    VALUE IN HEALTH, 2007, 10 (06) : A239 - A239
  • [46] Needs and cost-effectiveness in health care priority setting
    Erik Gustavsson
    Gustav Tinghög
    Health and Technology, 2020, 10 : 611 - 619
  • [47] Needs and cost-effectiveness in health care priority setting
    Gustavsson, Erik
    Tinghog, Gustav
    HEALTH AND TECHNOLOGY, 2020, 10 (03) : 611 - 619
  • [48] Cost-Effectiveness Thresholds: the Past, the Present and the Future
    Thokala, Praveen
    Ochalek, Jessica
    Leech, Ashley A.
    Tong, Thaison
    PHARMACOECONOMICS, 2018, 36 (05) : 509 - 522
  • [49] Future drug prices and cost-effectiveness analyses
    Hoyle, Martin
    PHARMACOECONOMICS, 2008, 26 (07) : 589 - 602
  • [50] ANTICIPATED FUTURE DIRECTIONS IN COST-EFFECTIVENESS ANALYSIS
    BLUMSTEIN, A
    OPERATIONS RESEARCH, 1975, 23 : B263 - B263